Diasorin Logo

Diasorin

ISIN

IT0003492391

Ticker

DIA

Sector

Health Care

Sub-Industry

Biotechnology

Country

Italy

Year Founded

2000

About Diasorin

Company Description

World leaders in the lab diagnostics market, we are specialists in the immunodiagnostics and molecular diagnostics segments and active in the Licensed Technology sector

The Company has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests and Licensed Technology solutions, made available thanks to ongoing investments in research, positions us as the player with the widest range of specialty solutions in the sector and identifies the Group as the "Diagnostics Specialist".

Diagnosis is the first step towards understanding a person’s state of health. This is why our tests can make the difference: they are precise and reliable and enable delivery of early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy.

Headcount

3,350

Served Area

Worldwide

Headquarters

Via Crescentino snc
13040, Saluggia
Italy

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A 26,000.00 26,000.00 26,000.00
Other Noncurrent Assets N/A 2,189,000.00 4,323,000.00 3,722,000.00
Current Trade Receivables N/A 165,678,000.00 217,588,000.00 220,035,000.00
Cash and cash equivalents 157,552,000.00 339,881,000.00 403,020,000.00 241,776,000.00
Other Current Assets N/A 16,998,000.00 39,634,000.00 89,184,000.00
Statutory Reserve N/A 11,190,000.00 11,190,000.00 11,190,000.00
Other Noncurrent Liabilities N/A 48,155,000.00 43,983,000.00 17,287,000.00
Trade And Other Current Payables To Trade Suppliers N/A 65,485,000.00 84,773,000.00 104,204,000.00
Other Current Payables N/A 60,688,000.00 102,319,000.00 103,304,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Profit (loss) 248,296,000.00 310,732,000.00 240,110,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 248,296,000.00 310,732,000.00 240,110,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 182,329,000.00 63,139,000.00 -161,244,000.00
Cash and cash equivalents 157,552,000.00 339,881,000.00 403,020,000.00 241,776,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 Italian 🇮🇹 Published: 30.05.2023
  • Consolidated Report 2021 - Q4 Italian 🇮🇹 Published: 30.05.2023

Capital Markets Information

ISIN

IT0003492391

LEI

8156002878BDF0EE4348

Sub-Industry

Biotechnology

Listed Stock Exchange

Borsa Italiana

Stock Index

FTSE MIB

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.